Abstract
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder of unknown aetiology. Progressive motor weakness and bulbar dysfunction lead to premature death, usually from respiratory failure. To date, riluzole is the only disease-modifying drug approved for the treatment of ALS, but this has only a minor impact on the clinical outcome. The clinical development of new drugs for ALS is entirely dependent on the understanding of the aetiology and pathophysiology of the disease, which is still far from being fully elucidated. ALS is a multisystem disorder and can be viewed as the consequence of a complex neurodegenerative process involving neuron-glia interactions. Excitotoxicity, oxidative stress, mitochondrial dysfunction, cytoskeletal defects and apoptosis are all putative mechanisms which seem to operate in ALS and might be amenable of pharmacological intervention. Since the pathogenesis of ALS seems to involve multiple factors, future treatments may target different molecular pathways by a combined multi-drug therapy.
Keywords: als, neuroprotection, clinical trials, excitotoxicity, oxidative stress, apoptosis
Current Neuropharmacology
Title: Possible Neuroprotective Strategies in ALS
Volume: 2 Issue: 3
Author(s): Simone Beretta, Laura Brighina and Carlo Ferrarese
Affiliation:
Keywords: als, neuroprotection, clinical trials, excitotoxicity, oxidative stress, apoptosis
Abstract: Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder of unknown aetiology. Progressive motor weakness and bulbar dysfunction lead to premature death, usually from respiratory failure. To date, riluzole is the only disease-modifying drug approved for the treatment of ALS, but this has only a minor impact on the clinical outcome. The clinical development of new drugs for ALS is entirely dependent on the understanding of the aetiology and pathophysiology of the disease, which is still far from being fully elucidated. ALS is a multisystem disorder and can be viewed as the consequence of a complex neurodegenerative process involving neuron-glia interactions. Excitotoxicity, oxidative stress, mitochondrial dysfunction, cytoskeletal defects and apoptosis are all putative mechanisms which seem to operate in ALS and might be amenable of pharmacological intervention. Since the pathogenesis of ALS seems to involve multiple factors, future treatments may target different molecular pathways by a combined multi-drug therapy.
Export Options
About this article
Cite this article as:
Beretta Simone, Brighina Laura and Ferrarese Carlo, Possible Neuroprotective Strategies in ALS, Current Neuropharmacology 2004; 2 (3) . https://dx.doi.org/10.2174/1570159043359684
DOI https://dx.doi.org/10.2174/1570159043359684 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
The Role of Sigma-1 Receptor, an Intracellular Chaperone in Neurodegenerative Diseases
Current Neuropharmacology Editorial [Hot Topic: Sigma Receptor Research: Progress Towards Diagnostic and Therapeutic Uses of Sigma Ligands (Executive Guest Editor: Carmen Abate )]
Current Pharmaceutical Design Nanoparticle-Mediated Drug Delivery: Blood-Brain Barrier as the Main Obstacle to Treating Infectious Diseases in CNS
Current Pharmaceutical Design Reorganizing Metals: the Use of Chelating Compounds as Potential Therapies for Metal-Related Neurodegenerative Disease
Current Topics in Medicinal Chemistry Mechanism of Tau-Induced Neurodegeneration in Alzheimer Disease and Related Tauopathies
Current Alzheimer Research Machine Learning Approaches in Parkinson’s Disease
Current Medicinal Chemistry Interactions of VDAC with Proteins Involved in Neurodegenerative Aggregation: An Opportunity for Advancement on Therapeutic Molecules
Current Medicinal Chemistry Nanotechnology and Antioxidant Therapy: An Emerging Approach for Neurodegenerative Diseases
Current Medicinal Chemistry A Review on Solvent-free Methods in Organic Synthesis
Current Organic Chemistry D-Serine Regulation: A Possible Therapeutic Approach for Central Nervous Diseases and Chronic Pain
Mini-Reviews in Medicinal Chemistry Glutamate Receptors in Human Caudate Nucleus in Normal Aging and Alzheimer’s Disease
Current Alzheimer Research The Role of local Insulin-like Growth Factor-1 Isoforms in the Pathophysiology of Skeletal Muscle
Current Genomics Human PON Promoters: From Similarity to Prediction of Polymorphic Positions within Transcription Factor Elements
Mini-Reviews in Medicinal Chemistry The Role of Autophagy in the Pathogenesis of Ischemic Stroke
Current Neuropharmacology PET Radioligands for In Vivo Visualization of Neuroinflammation
Current Pharmaceutical Design Glutamate Binding-Site Ligands of NMDA Receptors
Current Medicinal Chemistry Effect of Electromagnetic Radiations on Neurodegenerative Diseases- Technological Revolution as a Curse in Disguise
CNS & Neurological Disorders - Drug Targets Endothelium and Oxidative Stress: The Pandora's Box of Cerebral (and Non-Only) Small Vessel Disease?
Current Molecular Medicine Shoulder Manifestations of Diabetes Mellitus
Current Diabetes Reviews Meet Our Editorial Board Member
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)